Yann Roche’s Post

🌟 Accelerating  Drug Discovery in CNS Disorders 🌟 Billions are invested in drug discovery every year, yet the clinical failure rate remains dauntingly high. We understand the complexities and challenges our sponsors face in developing effective treatments for central nervous system (#CNS) disorders. 🔬 As a forerunner in the field of preclinical EEG, SynapCell benefits from unique expertise and know-how in this domain based on 20 years of experience. We offer a  comprehensive range of assays, from efficacy and derisking assays to model exploration, and ensures that drug candidates are thoroughly evaluated at every stage. Utilizing cutting-edge in vivo compound testing and EEG #biomarkers, we predict the efficacy of drug candidates early in the preclinical phase, significantly increasing the likelihood of clinical success. 🧠 Whether you are working on #epilepsy, #Parkinson’s disease or other movement disorders, #psychiatric and #neurodegenerative disorders, our translational #neuroscience expertise can guide you from discovery to successful clinical outcomes. Discover how SynapCell can revolutionize and accelerate your drug development process. Let's push the boundaries of neuroscience together! 🔗 Learn more about our services : https://synapcell.fr/ #DrugDiscovery #CNSdisorders  #PreclinicalResearch

On this #WorldBrainDay let's remember that brain disorders are a major source of suffering globally. With over 3.4 billion people affected by nervous system disorders and 11.1 million deaths annually, advancing research is imperative. This #WBD24, let’s prioritize collaboration and advancement of research. We at Aganitha are humbled to contribute to CNS research. Our recent collaboration with CSIR-CCMB to develop nanobody binders targeting GluD1 receptors is a significant stride for us in neuroscience and pharmacology. These nanobodies might serve as precise molecular tools to modulate GluD1 receptor activity, potentially unlocking novel therapeutic avenues for neurological disorders. Complementing wet lab techniques, in our recent preprint, we analyzed drug selectivity in an approved drug for relapsing forms of Multiple sclerosis. Our work shows that MD powered in silico studies can model and predict selectivity of candidate molecules to GPCRs, the largest family of drugs targeted by approved drugs. #WorldBrainDay 2024 provides an occasion to remind ourselves of the importance of these research activities & collaborations. Research into CNS disorders can alleviate individual suffering & have positive implications for all of humanity.  #WorldBrainDay #Neuroscience #BrainHealth #Aganitha #Biopharma #Innovation #Prevention #Awareness #Collaboration #Education #Advocacy #who #WBD  #CNS #neurological disorders #Alzheimer's #MS #Nanobody #Epilepsy #research

After a dynamic first half of 2024, the upcoming months are set to bring significant developments in neuropsychiatric and neurodegenerative disease research. Key data readouts are anticipated across Alzheimer’s, schizophrenia, depression, and rare diseases. Highlights include: 🧠 Athira Pharma’s Fosgonimeton for Alzheimer’s, showing promise in Phase II/III trials. 🧠 AbbVie/Cerevel Therapeutics’s Emraclidine for schizophrenia, with Phase II results expected soon. 🧠 Neumora Therapeutics’ Navacaprant for major depressive disorder, entering Phase III. 🧠 Amylyx Pharmaceuticals’s AMX0035 for Wolfram syndrome, following ALS treatment challenges. 🧠 Vigil Neuroscience’s Iluzanebart for ALSP, a rare neurological disease. Stay tuned for these pivotal updates that could reshape the treatment landscape for these critical conditions. #Neuroscience #ClinicalResearch #Alzheimers #Schizophrenia #Depression #RareDiseases #Biotech #Pharma #HealthcareInnovation https://lnkd.in/ejgBG4F9

𝗗𝗮𝗶𝗹𝘆 𝗡𝗲𝘂𝗿𝗼-𝗯𝗶𝘁𝗲𝘀 🧠: 🌟 Exciting Times Ahead in Neurological Disease Research! 🌟 The second half of 2024 promises ground-breaking developments in neuropsychiatric and neurodegenerative disease research. 𝗛𝗲𝗿𝗲 𝗮𝗿𝗲 𝗳𝗶𝘃𝗲 𝗸𝗲𝘆 𝗱𝗮𝘁𝗮 𝗿𝗲𝗮𝗱𝗼𝘂𝘁𝘀 𝘁𝗼 𝘄𝗮𝘁𝗰𝗵: 🥊Athira Pharma’s Fosgonimeton (#Alzheimer’sDisease): A novel treatment focusing on the HGF/MET system to enhance #neuroprotection and reduce #inflammation. Phase II/III trial results are expected soon! 💭AbbVie/Cerevel Therapeutics’s Emraclidine (#Schizophrenia): Following a $9B investment, Phase II trials aim to show rapid symptom improvement. Can emraclidine outpace competitors in the schizophrenia treatment race? ☔Neumora Therapeutics’ Navacaprant (#MajorDepressiveDisorder): This Kappa-opioid receptor antagonist offers a new approach to #MDD treatment. Phase III data expected to highlight its potential as a first-in-class therapy. ⚕️Amylyx Pharmaceuticals’s AMX003 (#WolframSyndrome): Following challenges with #ALS treatment, Amylyx is targeting this rare, multi-organ disease with promising Phase II interim results showing improved pancreatic function. 🧠Vigil Neuroscience’s Iluzanebart (ALSP): Aiming to treat the rare, inherited #ALSP, this Phase II trial explores a novel mechanism targeting microglial dysfunction. Could it be the breakthrough needed for this untreatable condition? Stay tuned for these pivotal updates that could transform patient care! #NeuroScience #ClinicalResearch #Pharma #Biotech #Alzheimers #Schizophrenia #Depression #RareDiseases https://lnkd.in/ePWKgnMr

Exciting News! We're thrilled to announce that we've initiated our First-in-Human Clinical Trial for the treatment of neurodevelopmental disorders. In this landmark achievement, we've successfully dosed the first two cohorts of subjects and we are moving forward to the third one in a first-in-human Phase 1 clinical trial of IAMA-6, our promising small molecule designed to target NKCC1. IAMA-6 is our lead clinical program, representing a breakthrough in addressing neurodevelopmental disorders. This highly selective small molecule, designed for oral administration, targets NKCC1-associated neuronal hyperexcitability. Preclinical studies have demonstrated its safety and efficacy, paving the way for its evaluation in a Phase 1 clinical trial. The therapeutic potential of IAMA-6 extends to a spectrum of neurodevelopmental disorders, including epilepsy and other central nervous system disorders, offering hope for patients and families affected by these conditions. Learn more about our mission at https://lnkd.in/d7ayaMWE #IAMAtherapeutics #Neurodevelopment #ClinicalTrial #Neuroscience #Biotech

This work from Sergiu P. Pașca's lab elegantly demonstrates a route to a potential cure for Timothy Syndrome Type 1 (TS1). It is groundbreaking, and through in vivo experiments including cells from TS1 individuals shows that antisense oligonucleotides (ASO) could provide a therapy for our community. The possibility of a neurological ASO clinical trial is wonderful, but balancing the risks of that work with the need for safe and validated therapies is crucial. This work is proof-of-concept. It demonstrates that targeted therapies are possible for TS1, and other neurodevelopmental disorders. For TS1 children, babies and their families there is hope. However, there are potential barriers to be overcome before this can be considered a treatment or a cure, and for the wider community of individuals with disease-causing genetic variants in #CACNA1C there is further to go on the journey.  We hope that the team at Stanford will continue to engage closely with our Patient Advocacy Organisation - the Timothy Syndrome Alliance (TSA) - as we work to improve the path to clinical diagnosis and provide knowledge and signposting to the CACNA1C community. Sophie Muir, Chair of Trustees, TSA and Dr Jack Underwood, NMHII, Cardiff University TSA Scientific Advisory Board  https://lnkd.in/eJ7TUXur #TimothySyndrome #RareDiseases #research #Neuroscience #LongQT8

Neuroplasticity plays a pivotal role in the development of neurological and psychiatric disorders. Identifying drugs that modulate neuroplasticity can potentially enhance or restore neural function, alleviating symptoms and slowing disease progression. Cellectricon’s suite of advanced in vitro models enables the study of various aspects of neuroplasticity, including synaptic, structural, and functional plasticity. The applications are extensive, ranging from identifying neuroplasticity-related targets to high-throughput drug discovery screens for optimizing drug candidates and building structure-activity relationships.   We excel in creating tailor-made solutions and apply a highly interactive services process to ensure that our Clients’ goals are realized. Discover how our services can leverage neuroplasticity in drug discovery to accelerate the development of novel, safer, and more effective treatments for neurological and psychiatric conditions! 🌟 Learn more about our services on: https://lnkd.in/eXAuZJGv #neuroscience #drugdiscovery #targetdiscovery #leaddiscovery #neurobiology #invitro #research #neuroplasticity

Our novel therapeutic approach targets a mechanism of action to promote #neurogenesis and #neuroprotection. Learn more about how dysreglations in this naturally occurring process leads to #neurologicaldisorders. https://lnkd.in/gmaxiKzx

📣 Call for Papers for an upcoming Special Issue in CNS & Neurological Disorders - Drug Targets, titled "Heart and Brain Axis Targets in CNS Neurological Disorders." 📣 As the guest editor for this Special Issue, I am excited to invite researchers, practitioners, and experts to contribute to this important issue that aims to explore therapeutic targets influencing cardiac and cerebral functions. We invite contributions on diverse aspects of the heart-brain axis, including neurovascular coupling and its implications for CNS disorders, the role of the blood-brain barrier in pathogenesis and drug action, and shared molecular mechanisms affecting treatment efficacy. We are also interested in exploring how cardiovascular risk factors, stress, and emotion impact neurological conditions, as well as the neurological complications of cardiovascular diseases such as stroke and cognitive impairment. Additionally, papers addressing the effects of aging, neurogenic heart disorders, inflammation, oxidative stress, and translational research on brain-heart interactions are highly encouraged. 📅 Submission Deadline: January 07, 2025 For more information on the subtopics and submission guidelines, please visit: https://lnkd.in/g_UzKdpU #HeartBrainAxis #NeurovascularCoupling #BloodBrainBarrier #CardiovascularRiskFactors #Psychocardiology #NeurogenicHeartDisorders #Inflammation #OxidativeStress #NeurobiologyOfHeartFailure #DualTargetedTherapeutics

Exciting to see our work being cited in new research! Congratulations to the SYNGAP1 team on this publication 🎉 Disruption of SYNGAP1 causes SYNGAP1-related intellectual disability (SRID), a neurodevelopmental disorder characterized by intellectual disability, motor impairments, and epilepsy. In this study, researchers utilized preclinical mouse models to uncover key biomarkers related to neuronal activity and function. Findings like these are critical to understanding and developing treatments for SRID. Check out the full study here: https://lnkd.in/eDAmijgQ #SYNGAP1 #Neurodevelopment #RareDiseaseResearch #TranslationalMedicine #IntellectualDisability